Gold Silver Reports (GSR) – Vedanta Declines Ahead Of Quarterly Results Announcement – Shares of the base metal producer extended declines for the second day and fell as much as 2.1 percent to Rs 277.35, ahead of its March quarter results announcement. Analysts surveyed by Bloomberg predict the company’s net profit to decline 13.7 percent on a yearly basis to Rs 2,579 crore.
Gold Silver Reports (GSR) – Iranians Go for Gold Amid Currency Turmoil, U.S. Tensions — Gold coin and bar demand in the Persian Gulf nation soared to 9.3 tons in the first quarter, a three-year high, on “investor concerns over worsening Iranian-U.S. relations and the prospect of currency controls,” the World Gold Council said Thursday in a report.
Gold Silver Reports (GSR) – China Shunning U.S. Soybeans on Trade Tensions — “Whatever they’re buying is non-U.S.,” Bunge Ltd. Chief Executive Officer Soren Schroder said in a telephone interview Wednesday. “They’re buying beans in Canada, in Brazil, mostly Brazil, but very deliberately not buying anything from the U.S.”
Gold Silver Reports (GSR) – Stocks in Asia Retreat After Fed — Asian stocks tracked U.S. shares lower after the Federal Reserve said inflation is close to its target, without indicating any need to waver from its path of gradually tightening monetary policy. The dollar declined.
Gold Silver Reports (GSR) – Siddharth Agrawal, Director, Godawari Power And Ispat – Key highlights from the conversation: ✅ Expect 15-20 percent growth in 2018-19. ✅ See 20 percent …
Gold Silver Reports (GSR) – Sical Logistics Stock Gains After WInning New Contract – Shares of the Chennai-based logistics services firm rose as much as 6.6 percent to Rs 224. The company was awarded a letter of acceptance by Northern Coalfields for mechanical excavations for a contract price of Rs 1,345 crores for excavation of 145 million bank cubic metre over a period of 51 months, according to its stock exchange notification.
Gold Silver Reports (GSR) – Biocon Stock Declines After FDA Issues Form 483 – Shares of the Bengaluru-based pharma company fell as much as 4.5 percent, most in almost two months, to Rs 634.3. The U.S. drug regulator issued form 483 with seven observations after completing pre-approval inspection of the company’s sterile drug product manufacturing facility at Bengaluru this week, according to the company’s exchange filing. Observations are largely procedural and not critical, aiming at continuous improvement, it added.